131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Status:
Not yet recruiting
Trial end date:
2030-07-30
Target enrollment:
Participant gender:
Summary
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan,
temozolomide, and bevacizumab for patients with recurrent medulloblastoma. A feasibility
cohort is included to assess the feasibility of incorporating cRIT 131I-omburtamab for
patients with recurrent ependymoma.
Direct intraventricular delivery of radiolabeled tumor-specific antibodies may aid in both
the detection and treatment of recurrent disease for these highly specific pediatric patients
with recurrent tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Pediatric Brain Tumor Consortium
Collaborators:
Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) Y-mAbs Therapeutics, Inc